SGLT2 inhibitors not tied to higher UTI risk in CKD study

A nationwide Korean target trial emulation compared urinary tract infection (UTI) and genital tract infection (GTI) risk between SGLT2 inhibitor and DPP-4 inhibitor initiators among 41,801 adults with type 2 diabetes and chronic kidney disease. The study reported no increased UTI risk with SGLT2i (HR 0.99) but a modest increase in GTI risk (HR 1.31), with no difference in severe infections requiring hospitalization or emergency visits between groups. The authors reported that excess GTI risk clustered early and was most pronounced among women aged 65-79 years, and that findings were consistent across multiple sensitivity analyses.

Most relevant for: Patients with type 2 diabetes and chronic kidney disease being considered for SGLT2 inhibitor therapy, particularly older women.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.